Academic Journal
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study
| العنوان: | Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFMALL 2000 study |
|---|---|
| المؤلفون: | Conter, V., Bartram, C.R. (Claus), Valsecchi, M.G. (Maria Grazia), Schrauder, A. (André), Panzer-Grümayer, R. (Renate), Möricke, A., Aricò, M. (Maurizio), Zimmermann, M. (Martin), Mann, G. (Georg), Rossi, G. (Giulio) de, Stanulla, M. (Martin), Locatelli, F. (Franco), Basso, G. (Giuseppe), Niggli, F. (Felix), Barisone, E. (Elena), Henze, G. (Günter), Ludwig, W.D., Haas, O.A. (Oskar), Cazzaniga, G. (Gianni), Koehler, R. (Rolf), Silvestri, D. (Daniela), Bradtke, J. (Jutta), Parasole, R. (Rosanna), Beier, R. (Rita), Dongen, J.J.M. (Jacques) van, Biondi, A. (Andrea), Schrappe, M. (Martin) |
| المصدر: | Blood vol. 115 no. 16, pp. 3206-3214 |
| سنة النشر: | 2010 |
| المجموعة: | RePub - Publications from Erasmus University, Rotterdam |
| الوصف: | The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10-4); MRD high risk (MRD-HR) if 10-3or more at day 78 and MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3). Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and NCT00613457 for AIEOP. (Blood. 2010;115(16):3206-3214) |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | http://repub.eur.nl/pub/27581; urn:hdl:1765/27581 |
| DOI: | 10.1182/blood-2009-10-248146 |
| الاتاحة: | http://repub.eur.nl/pub/27581 https://doi.org/10.1182/blood-2009-10-248146 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.6FEF5E37 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1182/blood-2009-10-248146 |
|---|